中外製薬（4519） – Supplementary Materials for Consolidated Financial Results for the 1st Quarter of Fiscal Year 2022. 12 (IFRS)

Supplementary Materials forConsolidated Financial Results forthe 1st Quarter of Fiscal Year 2022. 12 (IFRS)Chugai Pharmaceutical co., ltd.Notes: 1.Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available atthe time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.3.Exchange rates used for each period are as follows.QTRCHFEURUSDSGDYTD*Market average exchange rateActual*FY20201-12Full-yearCHFEURUSDSGD113.72121.69106.8077.41*Market average exchange ratePeriod-endActualFY202031 Dec.117.10126.89103.1977.98CHFEURUSDSGD1-3QTR117.08127.65105.8379.474-6QTR120.11131.87109.4482.127-9QTR119.88129.78110.0881.3910-12QTR123.26130.02113.6683.751-3QTR125.78130.43116.1785.92(Yen)Actual*FY20224-6QTR7-9QTR10-12QTR1-9YTD1-12Full-year1-3YTD1-6YTD1-9YTD1-12Full-yearFull-year1-3YTD117.08127.65105.8379.471-6YTD118.60129.76107.6380.80119.03129.77108.4581.00120.10129.83109.7581.69125.78130.43116.1785.92AssumptionFY20221-12122.00130.00112.0084.00Actual*FY2021Actual*FY2021ActualFY2021Actual*FY2022ActualFY202231 Mar.30 Jun.30 Sep.31 Dec.31 Mar.30 Jun.30 Sep.31 Dec.117.14129.30110.3781.87120.02131.48110.5282.15119.76129.85111.9782.27125.95130.31115.0785.09131.93135.92121.8290.07Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　1Reconciliation of IFRS results to Core resultsIFRS resultsOthersCore results IFRS resultsOthersCore resultsFY20211-3Intangibleassets168.8130.338.6-(55.3)113.5(49.5)(15.9)(29.7)(3.9)64.0(0.0)0.3-64.2(16.8)47.447.4—–0.30.30.0-0.0-0.3—0.3(0.1)0.20.2——-1.10.01.00.01.1—1.1(0.3)0.80.8-168.8130.338.6-(55.0)113.8(48.5)(15.8)(28.7)(3.9)65.4(0.0)0.3-65.6(17.2)48.448.4-360.6242.725.991.9(114.4)246.1(59.1)(16.8)(33.9)(8.5)187.0(0.0)1.6(2.4)186.2(54.4)131.8131.8-(Billions of yen)FY20221-3Intangibleassets—-0.30.30.2-0.2-0.4—0.4(0.1)0.30.3-(91.9)–(91.9)-(91.9)3.40.10.82.5(88.5)—(88.5)27.0(61.5)(61.5)-268.6242.725.9-(114.1)154.5(55.6)(16.7)(32.9)(6.0)98.9(0.0)1.6(2.4)98.1(27.5)70.670.6-RevenuesSalesRoyalties and other operating incomeOther revenueCost of salesGross profitOperating expensesMarketing and distributionResearch and developmentGeneral and administrationOperating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsCore results Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjustingnon-recurring items recognized by Chugai to IFRS results. Chugai’s recognition of non-recurring items may differ from that of Roche due tothe difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internalperformance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.The table above shows the reconciliation of IFRS results into Core results. The detail is as below.Amortization （0.3 billion yen in 2021 and 0.3billion yen in 2022)Impairment （None in 2021 and 0.2billion in 2022）Intangible assetsOthersIncome from settlement agreement （None in 2021 and -91.9billion yen in 2022）Restructuring expenses etc. （1.1 billion yen in 2021 and 3.4billion yen in 2022）Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　23564ActualFY2021ActualFY2022(Billions of yen)1-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)IFRS results (QTR)RevenuesSales　Domestic　OverseasOther revenueCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsEarnings per shareBasic (yen)Diluted (yen)(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)168.8130.394.935.438.636.62.0-(55.3)42.4113.567.2(49.5)29.3(15.9)9.4(29.7)17.6(3.9)2.364.037.9(0.0)0.3-64.238.0(16.8)47.428.147.4-28.8428.82221.4173.9108.565.347.546.70.8-(68.1)39.2153.469.3(56.6)25.6(17.9)8.1(33.6)15.2(5.2)2.396.743.7(0.0)0.3(0.0)97.043.8(26.3)70.731.970.7-43.0242.99287.3234.5159.275.352.752.10.6-(104.2)44.4183.163.7(60.9)21.2(18.5)6.4(36.2)12.6(6.3)2.2122.242.5(0.0)0.3(2.8)119.741.7(33.7)86.029.986.0-52.3152.28322.3264.1156.3107.858.151.86.4-(110.6)41.9211.765.7(72.6)22.5(24.3)7.5(37.8)11.7(10.5)3.3139.143.2(0.0)(0.9)0.3138.442.9(39.6)98.830.798.8-60.1160.08360.6 +113.6242.7+86.3161.7+70.481.0 +128.825.9(32.9)25.2(31.1)0.7(65.0)91.9-(114.4) +106.947.1-246.1 +116.8-68.2(59.1)+19.416.4-(16.8)+5.7-4.7(33.9)+14.1-9.4(8.5) +117.9-187.0 +192.2-51.9(0.0)0.01.6 +433.3(2.4)-186.2 +190.0-51.6(54.4) +223.8131.8 +178.1-36.62.4131.8 +178.1–80.14 +177.980.09 +177.9Other financial income (expense) includes net amount of FX related gains/losses. Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　323ActualFY2021ActualFY20201-12YTD1-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)(Billions of yen)ActualFY2022IFRS results (YTD)RevenuesSales　Domestic　OverseasOther revenueCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsEarnings per shareBasic (yen)Diluted (yen)(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)786.9633.3409.1224.2153.6129.624.1- (273.5)43.2513.565.3(212.3)27.0(72.6)9.2(117.9)15.0(21.8)2.8301.238.3(0.1)(1.5)(1.5)298.237.9(83.5)214.727.3214.7- 168.8130.394.935.438.636.62.0- (55.3)42.4113.567.2(49.5)29.3(15.9)9.4(29.7)17.6(3.9)2.364.037.9(0.0)0.3- 64.238.0(16.8)47.428.1390.2304.1203.4100.786.183.32.8- (123.4)40.6266.868.4(106.2)27.2(33.8)8.7(63.3)16.2(9.1)2.3160.741.2(0.0)0.6(0.0)161.341.3(43.1)118.130.3677.5538.7362.6176.0138.8135.43.4- (227.6)42.2449.966.4(167.1)24.7(52.2)7.7(99.5)14.7(15.3)2.3282.841.7(0.0)0.9(2.8)280.941.5(76.8)204.230.1999.8802.8518.9283.9196.9187.29.8- (338.1)42.1661.666.2(239.7)24.0(76.6)7.7(137.3)13.7(25.8)2.6421.942.2(0.0)0.1(2.5)419.441.9(116.4)303.030.3(65.0)-(114.4) +106.9-+116.8+113.6+86.3+70.4+128.8(32.9)(31.1)-+19.4-+5.7-+192.2-0.0-+433.3+190.0360.6242.7161.781.025.925.20.791.947.1246.168.2(59.1)16.4(16.8)4.7(33.9)9.42.4187.051.9(0.0)1.6(2.4)186.251.6+14.1-(8.5) +117.9–(54.4) +223.8131.8+178.136.6-47.4- 118.1- 204.2- 303.0 – 131.8 -+178.1- 130.66130.53 28.8428.82 71.8671.81 124.17124.09 184.29184.1780.1480.09+177.9+177.9Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.“Earnings per share (Basic)” and “Earnings per share (Diluted)” presents the amount after the stock split.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　4356(Billions of yen)4ActualFY2021ActualFY20221-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)Core results (QTR)RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeMarketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interests(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)322.3264.1156.3107.858.151.86.4(109.8)41.6212.565.9(69.1)21.4(23.6)7.3(35.7)11.1(9.9)3.1143.444.5(0.0)(0.9)0.3142.744.3(40.9)101.831.6168.8130.394.935.438.636.62.0(55.0)42.2113.867.4(48.5)28.7(15.8)9.4(28.7)17.0(3.9)2.365.438.7(0.0)0.3- 65.638.9(17.2)48.428.748.4- 29.42221.4173.9108.565.347.546.70.8(66.8)38.4154.669.8(54.1)24.4(18.1)8.2(31.1)14.0(4.9)2.2100.545.4(0.0)0.3(0.0)100.845.5(27.4)73.333.173.3- 44.58287.3234.5159.275.352.752.10.6(103.8)44.3183.463.8(58.5)20.4(18.2)6.3(34.3)11.9(6.0)2.1124.943.5(0.0)0.3(2.8)122.542.6(34.5)87.930.687.9- 53.45268.6242.7161.781.025.925.20.7(114.1)47.0154.557.5(55.6)20.7(16.7)6.2(32.9)12.2(6.0)2.298.936.8(0.0)1.6(2.4)98.136.5(27.5)70.626.3+59.1+86.3+70.4+128.8(32.9)(31.1)(65.0)+107.5-+35.8-+14.6-+5.7-+14.6-+53.8-+51.2-0.0+433.3-+49.5-+59.9+45.9-+45.9-+45.9Core earnings per share (diluted) (yen) 101.8-61.9070.6- 42.91Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.Other financial income (expense) includes net amount of FX related gains/losses. Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　51-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)ActualFY2022Core results (YTD)66666ActualFY2021390.2304.1203.4100.786.183.32.8(121.9)40.1268.468.8(102.5)26.3(34.0)8.7(59.9)15.4(8.7)2.2165.842.5(0.0)0.6(0.0)166.442.6(44.7)121.731.2677.5538.7362.6176.0138.8135.43.4(225.7)41.9451.866.7(161.1)23.8(52.2)7.7(94.1)13.9(14.7)2.2290.742.9(0.0)0.9(2.8)288.942.6(79.2)209.731.0168.8130.394.935.438.636.62.0(55.0)42.2113.867.4(48.5)28.7(15.8)9.4(28.7)17.0(3.9)2.365.438.7(0.0)0.3- 65.638.9(17.2)48.428.7RevenuesSales　Domestic　OverseasCost of salesGross profitOperating expensesRoyalties and other operating income　Royalty and profit-sharing income　Other operating income(% of Sales)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)(% of Revenues)Marketing and distribution Research and development General and administration Operating profitFinancing costsOther financial income (expense)Other expenseProfit before taxesIncome taxesNet incomeAttributable toChugai shareholdersNon-controlling interestsWeighted average number of shares in issueused to calculate diluted earnings per share(Millions of shares)Core earnings per share (diluted) (yen)Core payout ratio (%)Dividend per share (Full year) (yen)Dividend per share (Year end) (yen)Dividend per share (Half year) (yen)ActualFY20201-12YTD786.9633.3409.1224.2153.6129.624.1(272.3)43.0514.765.4(206.7)26.3(71.5)9.1(113.5)14.4(21.7)2.8307.939.1(0.1)(1.5)(1.5)304.938.7(85.5)219.427.9219.4- 133.3941.2-3075268.6242.7161.781.025.925.20.7+59.1+86.3+70.4+128.8(32.9)(31.1)(65.0)(114.1) +107.5-+35.8-+14.6-+5.7-+14.6-+53.8-+51.2-0.0+433.3-+49.5-+59.9+45.9-47.0154.557.5(55.6)20.7(16.7)6.2(32.9)12.2(6.0)2.298.936.8(0.0)1.6(2.4)98.136.5(27.5)70.626.3999.8802.8518.9283.9196.9187.29.8(335.5)41.8664.366.4(230.2)23.0(75.8)7.6(129.8)13.0(24.6)2.5434.143.4(0.0)0.1(2.5)431.643.2(120.1)311.531.2189.3540.176463048.4- 121.7- 209.7- 311.5 – 70.6-+45.9-1,6451,6451,6451,6451,6451,6450.0 29.42 73.99 127.45 42.91+45.9Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.Other financial income (expense) includes net amount of FX related gains/losses. Effective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock. Core EPS presents the amount after the stock split.Weighted average number of shares in issue used to calculate diluted earnings per share presents the amount after the stock split.The dividend for the second quarter of the fiscal year 2020 presents the amount prior to the stock split.The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.(Billions of yen)Forecast(Feb 3thannounced)FY2022Change(%) 1-12YTD1,150.01,031.5646.3385.2118.5114.04.5(460.0)44.6690.060.0(250.0)21.7 +15.0+28.5+24.6+35.7(39.8)(39.1)(54.1)+37.1-+3.9-+8.6-(149.5)13.0+15.2- 440.038.3+1.4- 312.527.2+0.3-190.0040.0763838+0.3—-Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　6ActualFY2021ActualFY20221-3QTR4-6QTR7-9QTR10-12QTR1-3QTRChange(%)4-6QTRChange(%)7-9QTRChange(%)10-12QTRChange(%)Core statements of revenues (QTR)SalesDomesticOncologyAvastinTecentriqPerjetaAlecensaPolivyKadcylaHerceptinGazyvaRituxanFoundation MedicineOther productsPrimaryRonapreveHemlibraActemraEnspryngEdirolMirceraEvrysdiCellCeptBonvivaOxarolOther productsOverseasHemlibra To RocheActemra To RocheAlecensa To RocheEnspryng To RocheNeutroginOther productsRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeRevenuesDomesticOverseas130.394.957.918.814.17.46.0-3.22.61.01.21.02.636.9-8.89.21.42.93.4-2.02.01.45.835.48.58.017.416.96.05.6–2.21.238.636.62.0168.895.373.6173.9108.566.220.416.48.27.10.94.02.61.11.21.23.142.3-9.911.02.24.73.6-2.22.11.55.165.324.724.220.519.715.014.50.90.92.51.747.546.70.8221.4109.0112.4234.5159.267.020.615.58.17.02.64.12.31.11.21.33.192.342.810.611.62.69.93.70.42.02.01.65.075.328.527.825.624.917.216.70.30.32.11.652.752.10.6287.3159.8127.5264.1156.370.421.116.18.57.53.34.42.31.21.51.62.985.934.612.311.43.54.93.71.92.22.11.67.6107.852.552.039.338.711.811.30.30.32.31.758.151.86.4322.3158.3164.0242.7161.758.416.513.47.46.32.74.11.81.01.01.62.6103.260.810.09.93.33.32.62.11.81.71.46.381.044.744.225.724.65.24.61.21.22.41.925.925.20.7268.6162.7105.9+86.3+70.4+0.9(12.2)(5.0)0.0+5.0-+28.1(30.8)0.0(16.7)+60.00.0+179.7-+13.6+7.6+135.7+13.8(23.5)-(10.0)(15.0)0.0+8.6+128.8+425.9+452.5+47.7+45.6(13.3)(17.9)–+9.1+58.3(32.9)(31.1)(65.0)+59.1+70.7+43.9Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　7ActualFY20201-12YTDActualFY20211-3YTD1-6YTD1-9YTD1-12YTD1-3YTDChange(%)1-6YTDChange(%)1-9YTDChange(%)1-12YTDChange(%)ActualFY2022Core statements of revenues (YTD)SalesDomesticOncologyAvastinTecentriqPerjetaAlecensaPolivyKadcylaHerceptinGazyvaRituxanFoundation MedicineOther productsPrimaryRonapreveHemlibraActemraEnspryngEdirolMirceraEvrysdiCellCeptBonvivaOxarolOther productsOverseasHemlibra To RocheActemra To RocheAlecensa To RocheEnspryng To RocheNeutroginOther productsRoyalties and other operating income　Royalty and profit-sharing income　Other operating incomeRevenuesDomesticOverseas633.3409.1232.381.537.533.526.0-10.215.94.67.22.813.0176.8-34.139.31.327.817.5-9.18.96.432.4224.226.124.6134.4132.044.343.05.65.69.04.8153.6129.624.1786.9419.0368.0130.394.957.918.814.17.46.0-3.22.61.01.21.02.636.9-8.89.21.42.93.4-2.02.01.45.835.48.58.017.416.96.05.6–2.21.238.636.62.0168.895.373.6304.1203.4124.139.230.515.713.10.97.25.22.12.42.25.779.3-18.720.33.57.67.1-4.14.13.011.0100.733.232.237.936.521.120.10.90.94.83.086.183.32.8390.2204.3185.9538.7362.6191.159.846.123.820.13.511.27.53.23.63.58.8171.642.829.331.96.217.510.70.46.26.14.616.0176.061.760.063.561.538.336.91.21.26.84.6138.8135.43.4677.5364.1313.4802.8518.9261.580.962.232.227.76.815.79.84.55.15.111.6257.477.441.643.29.722.314.42.38.48.26.223.6283.9114.2112.0102.8100.150.148.21.51.59.16.2196.9187.29.8999.8522.3477.4242.7161.758.416.513.47.46.32.74.11.81.01.01.62.6103.260.810.09.93.33.32.62.11.81.71.46.381.044.744.225.724.65.24.61.21.22.41.925.925.20.7268.6162.7105.9+86.3+70.4+0.9(12.2)(5.0)0.0+5.0-+28.1(30.8)0.0(16.7)+60.00.0+179.7-+13.6+7.6+135.7+13.8(23.5)-(10.0)(15.0)0.0+8.6+128.8+425.9+452.5+47.7+45.6(13.3)(17.9)–+9.1+58.3(32.9)(31.1)(65.0)+59.1+70.7+43.9(Billions of yen)Forecast(Feb 3thannounced)FY2022(3.0)(0.3)(0.4)(35.3)(19.6)(15.3)(14.2)+4.7+3.6+1.9+78.4+20.0+24.6+28.5+138.2Change(%) 1-12YTD1,031.5646.3260.569.462.033.728.716.216.08.35.44.19.17.5385.8+49.9199.0 +157.151.8+24.541.916.710.810.28.87.47.05.127.1385.2186.0182.7144.4141.534.132.04.64.58.87.4118.5114.04.5 +282.6+206.7+200.0+14.8+35.7+62.9+63.1+40.5+41.4+19.4+72.2(14.6)(11.9)(17.7)(31.9)(33.6)(39.8)(54.1)(39.1)(29.2)(51.6)(3.3) 1,150.0649.0501.0+15.0+24.3+4.9Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　8Mar. 31Jun. 30Sep. 30Dec. 31Mar. 31Jun. 30vs. Jun. 30, 2021 vs. Dec. 31, 2021Sep. 30vs. Sep. 30, 2021 vs. Dec. 31, 2021Dec. 31vs. Dec. 31, 2021ActualFY2022(Billions of yen)Financial position Trade accounts receivable Inventories Trade accounts payable Other net working capital Net working capital Property, plant and equipment Right-of-use assets Intangible assets Other long-term assets – net Long-term net operating assets Net operating assets Debt Marketable securities Cash and cash equivalents Net cash Other non-operating assets – net Net non-operating assets Total net assets Total net assetsTotal assetsTotal liabilitiesAttributable toActualFY2020Dec. 31ActualFY2021195.6183.9(58.3)(21.2)300.0289.28.323.924.6346.0646.0-166.3212.3378.6(44.6)334.0980.0138.4184.7(42.1)0.3281.3291.47.426.025.5350.3631.6-181.3162.0343.47.7351.0982.6180.5199.2(68.7)4.0315.0310.66.325.324.7366.8681.8-204.1187.1391.2(21.0)370.21,052.1223.2201.4(100.7)0.6324.5327.65.624.825.7383.7708.2-204.1192.5396.6(14.2)382.51,090.6281.3208.8(97.2)(22.9)370.1338.813.322.028.4402.4772.6-204.2267.8472.0(56.5)415.51,188.0256.9225.5(111.2)52.9424.1348.412.824.924.8410.9834.9-201.3230.5431.8(26.2)405.61,240.5vs. Mar. 31, 2021 vs. Dec. 31, 2021(24.4)16.7(14.0)75.854.09.6(0.5)2.9(3.6)8.562.3-(2.9)(37.3)(40.2)30.3(9.9)52.5118.540.8(69.1)52.6142.857.05.4(1.1)(0.7)60.6203.3-20.068.588.4(33.9)54.6257.91,235.5(255.5)1,144.6(162.0)1,275.8(223.7)1,353.4(262.7)1,538.7(350.7)1,584.9(344.4)440.3(182.4)46.26.352.5-Chugai shareholdersNon-controlling interests980.0-982.6-1,052.1-1,090.6-1,188.0-1,240.5-257.9- Trade accounts receivable: trade receivable and notes receivable Trade accounts payable: trade payable and notes payable Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc. Other long-term assets-net: long-term prepaid expenses, long-term provisions etc. Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc. Net operating assets (NOA) and Net assets:The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA)and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) andNet assets of IFRS have been excluded, as the Core results concept only applies to the income statement. Net operating assets (NOA):Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital,long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　91-3YTD1-6YTD1-9YTD1-12YTD1-3YTD1-6YTD1-9YTD1-12YTD(Billions of yen)ActualFY2022Cash flowsOperating profit – IFRS basis Depreciation and impairment of property, plant and equipment Depreciation and impairment of right-of-use assets Amortization and impairment of intangible assets Other cash adjustment on operating profitOperating profit, net of operating cash adjustments (Increase) decrease in trade accounts receivable (Increase) decrease in inventories Increase (decrease) in trade accounts payable Change in other net working capital etc. Investment in property, plant and equipment Lease liabilities paid Investment in intangible assetsTotal (increase) decrease in net working capital etc.Operating free cash flowsas % of revenuesTreasury activities (interest income/expenses, foreign exchange gains/losses etc.)Settlement for transfer pricing taxationTax paidFree cash flowsDividends paidTransaction in own equity instrumentsPurchase of non-controlling interestsNet effect of currency translation on net cashNet change in net cashActualFY20201-12YTD301.222.35.53.62.9335.5(55.9)3.310.5(22.3)(64.4)(57.0)(8.4)(4.3)201.225.6%2.5(1.5)(66.8)135.4(91.4)0.4- 1.245.5ActualFY2021160.710.52.84.02.7180.715.4(15.6)10.0(22.7)(12.9)(35.4)(4.3)(4.4)123.731.7%0.5(0.0)(64.3)59.9(49.3)0.2- 1.812.6282.815.74.36.03.8312.6(27.2)(18.1)41.9(18.1)(21.5)(58.1)(6.3)(6.9)219.832.4%0.9(2.8)(103.6)114.3(98.3)0.3- 1.818.064.05.31.30.70.972.257.4(1.0)(16.5)0.340.2(28.9)(2.2)(2.9)78.346.4%(2.5)- (63.3)12.4(49.0)0.2- 1.2(35.2)421.921.05.910.37.3466.4(85.2)(25.5)38.1(10.5)(83.1)(66.0)(9.0)(6.9)301.430.1%(5.4)(2.5)(104.1)189.4(98.6)0.3- 2.393.4187.05.51.20.83.4197.924.6(16.1)13.8(55.5)(33.2)(34.1)(1.8)(2.6)126.235.0%(4.3)(2.4)(85.5)33.9(75.2)0.1- 0.9(40.2)Other cash adjustment on operating profit: adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, reserve for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in reserves) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds　from the sales of assets and reserve payments.Operating free cash flow (Operating FCF): pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,”　which shows the company’s cash generation ability from operating activities.Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt、changes in equity are included.The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.Free cash flow (FCF):The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of theconsolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results conceptonly applies to the income statement.Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for Consolidated Financial Results for the 1st quarter of FY2022(IFRS)　　　10Actual20201-12Actual2021Units1-12As of Dec. 31 As of Mar. 31 As of Jun. 30 As of Sep. 30 As of Dec. 31 As of Mar. 31 As of Jun. 30 As of Sep. 30 As of Dec. 311-121-31-61-91-31-61-9Actual2022Forecast (Feb 3thannounced)20221-12As of Dec. 31732.2 644.8 567.3 498.5 399.1 425.1 Key Performance indicatorsTotal indicatorCore return on invested capital (Core ROIC)Return on invested capital (ROIC)Ratio of profit to total assets (ROA)Ratio of equity attributable toChugai shareholdersRatio of equity attributable toChugai shareholders (stock price base)Price book value ratio（PBR)Ratio of net income to equity attributable toChugai shareholders (ROE)Margin indicator (Core)ROSCOS ratio（vs. Prod. sales）M&D cost ratioR&D cost ratioG&A cost ratioTurn over indicatorTotal asset turnorverWorking capital turnoverInventory turnoverReceivables turnoverPayables turnoverFixed asset turnoverPP&E turnoverintangible assets turnoverDividend / per stock indicatorDividends per share (Half year) Dividends per share (Year end)Dividends per share (Full year)Core earnings per share (diluted) Core payout ratio (%)Equity per share attributableto Chugai shareholders (BPS)Ratio of dividends to equity attributable toChugai shareholders (DOE)Cashflow indicatorCash conversion cycle（CCC）Net cash turnover periodNumber of employees Investment on property, plant and equipmentDepreciationInvestment on intangible assetsAmortizationtimes%%%%%%%%%%%%%MonthsMonthsMonths%%%YenYenYenYen%Yen%37.336.518.7 79.3 9.2 23.4 39.143.09.114.42.868.6131.98.13.72.6257.9288.93,319.07530-133.39 41.29.99.25.87,55575.222.03.92.97.57.44.0 85.8 7.5 4.8 38.742.29.417.02.314.226.410.03.22.352.258.2676.618.217.79.4 82.5 6.9 11.6 42.540.18.715.42.231.230.415.8 80.6 6.2 19.7 42.941.97.713.92.231.158.89.73.63.3117.6130.11,587.952.3100.18.03.74.0199.5219.72,783.944.343.121.8 77.2 5.2 28.0 43.441.87.613.02.572.1141.07.44.23.4287.5318.44,360.5304676189.35 40.111.5 8.25.77,66472.021.08.44.08.916.58.4 78.3 5.4 10.9 36.847.06.212.22.223.144.95.93.22.994.9104.91,538.56.23.67,64215.95.53.70.629.42 73.99 127.45 42.91 596.16 597.67 639.86 663.31 722.50 754.35 MonthsMonthsBillions of yenBillions of yenBillions of yenBillions of yen10.96.17,4907.45.32.90.79.96.07,67932.810.55.42.47.75.37,67455.015.76.93.338.344.613.0383876190.0040.070.023.0Core ROIC：Core net operting profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes)ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholdersTotal asset turnorver: Revenues / Total asset, CCC：[Trade accounts receivable/Sales＋（Inventories – Trade accounts payable）/Cost of sales]* passed monthsNet cash turnover period：Net cash/Revenue* passed monthsCore ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualizedThe Adjusted figures are used for calculating average NOA for Core ROIC and ROICEffective July 1, 2020, Chugai Pharmaceutical Co., Ltd. (“Chugai”) implemented a three-for-one stock split of its common stock.The dividend for the second quarter of the fiscal year 2020 presents the amount prior to the stock split.The annual dividend per share for the fiscal year ended December 31, 2020 is not stated because the amounts cannot be simply combined due to the implementation of the stock split.The annual dividend per share is ¥165 when calculated based on the assumption of no stock split, and ¥55 when calculated with the stock split taken into account.Core EPS and BPS presents the amount after the stock split. Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 11 ■Oncology ■Immunology ■Neuroscience ■Hematology ■Ophthalmology ■Other Diseases Development Pipeline [Main table] (as of April 25, 2022) Development code Origin Generic name Product name Indication # Additional indication (Combination drug) Country/region Projected submission Mode of Action Modality (Dosage form) atezolizumab Tecentriq polatuzumab vedotin Polivy obinutuzumab Gazyva tocilizumab Actemra emicizumab Hemlibra Filed RG7446 Roche RG7596 Seagen RG7159 GlycArt Biotechnology MRA/RG1569 in-house ACE910 /RG6013 in-house Phase III AF802/RG7853 in-house alectinib Alecensa RG7446 Roche atezolizumab Tecentriq Non-small cell lung cancer (NSCLC) (adjuvant) # Japan July 2021 Engineered anti-PD-L1 monoclonal antibody Antibody (IV) Diffuse large B-cell lymphoma (DLBCL) (1st Line) # (Rituxan+Chemo) Japan December 2021 Anti-CD79b antibody-drug conjugate Antibody (IV) Chronic lymphocytic leukemia* # (acalabrutinib) Japan March 2022 Glycoengineered type II anti-CD20 monoclonal COVID-19 pneumonia* # US April 2022 Acquired hemophilia A # Hemophilia A (mild-moderate)* # Japan EU November 2021 Q2 2021 Anti-coagulation monoclonal antibody Antibody (SC) antibody Antibody (IV) Humanized anti-human IL-6 receptor monoclonal antibody Antibody (IV) Roche factor IXa/X humanized bispecific Roche ALK inhibitor Small molecule (oral) Engineered anti-PD-L1 monoclonal antibody Antibody (IV) NSCLC (adjuvant) # Global 2023 NSCLC (neoadjuvant) # NSCLC (2nd Line)* (cabozantinib) Urothelial carcinoma (1st Line) # Muscle-invasive bladder cancer (adjuvant) # Renal cell carcinoma (adjuvant) # Renal cell carcinoma (2nd Line) # (cabozantinib) Early breast cancer (adjuvant) # Early breast cancer (neoadjuvant) # Ovarian cancer (1st Line) # (Avastin) # Japan 2023 Japan 2023 Japan Japan Japan Japan Japan Japan 2023 2024 2022 2023 2025 and beyond 2025 and beyond Japan 2022 Partner Roche Roche Nippon shinyaku Roche Roche Roche Takeda Roche Roche Roche Takeda Roche Roche Roche Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 12 ■Oncology ■Immunology ■Neuroscience ■Hematology ■Ophthalmology ■Other Diseases Development code Origin Generic name Product name Indication # Additional indication (Combination drug) Mode of Action Modality (Dosage form) Partner Hepatocellular carcinoma (HCC) (adjuvant) # (Avastin) # HCC (intermediate stage) # (Avastin) # HCC (2nd Line)* (lenvatinib or sorafenib) Head and neck carcinoma (adjuvant) # Prostate cancer (2nd Line)* # (cabozantinib) Small cell lung cancer (SCLC) (1st Line) # (Tecentriq) RG435 Roche bevacizumab Avastin RG7440 Array BioPharma RG6264 Roche ipatasertib Prostate cancer (1st Line) (abiraterone) trastuzumab /pertuzumab Breast cancer RG6058 Roche tiragolumab SCLC (1st Line) (Tecentriq) NSCLC (1st Line) (Tecentriq) NSCLC (stage III) (Tecentriq) # Esophageal cancer (Tecentriq) # RG6171 Roche RG7828 Roche RG6396 Blueprint Medicines giredestrant Breast cancer (adjuvant) mosunetuzumab pralsetinib Breast cancer (1st Line) (palbociclib + letrozole) Follicular lymphoma (2nd Line) (lenalidomide) NSCLC (1st Line) (pembrolizumab) Country/region Japan Projected submission 2023 Japan Japan Japan Japan Japan/ China 2025 and beyond 2025 and beyond 2022 – 2023 Japan 2023 Japan 2022 Japan － Japan 2023 Japan 2024 Japan 2024 Japan Japan Japan 2025 and beyond 2025 and beyond 2025 and beyond (Vascular Endothelial Growth Factor) Anti-VEGF humanized monoclonal antibody Antibody (IV) AKT inhibitor Small molecule (Oral) inhibitory humanized monoclonal Anti-HER2 humanized monoclonal antibody/ HER2 dimerization antibody Antibody (Fixed-dose combination, SC) Anti-TIGIT human monoclonal antibody Antibody (IV) SERD (Selective Estrogen Receptor Degrader) Small molecule (Oral) Anti-CD20/CD3 bispecific antibody Antibody (IV) Japan 2024 RET inhibitor Small molecule (Oral) Roche Roche Roche Roche Takeda Roche (China) Roche Roche Roche Roche Roche Roche Roche Roche Roche Roche Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 13 ■Oncology ■Immunology ■Neuroscience ■Hematology ■Ophthalmology ■Other Diseases Development code Origin Generic name Product name Indication # Additional indication (Combination drug) SA237/RG6168 in-house satralizumab Enspryng Generalized myasthenia gravis (gMG) # Country/region Global Projected submission 2024 Partner receptor Roche gantenerumab Alzheimer’s disease Japan 2023 tominersen Huntington’s disease Japan － delandistrogene moxeparvovec Duchenne muscular dystrophy (DMD)* Japan 2024 SKY59/RG6107 in-house crovalimab Paroxysmal nocturnal hemoglobinuria (PNH) Atypical hemolytic uremic syndrome (aHUS) Retinal vein occlusion # faricimab Vabysmo ralmitaront Schizophrenia SKY59/RG6107 in-house crovalimab Sickle cell disease (SCD)* Global Global 2023 (China: 2022) 2024 Japan 2023 RG1450 MorphoSys RG6042 Ionis RG6356/ SRP-9001 Sarepta Pharmaceuticals Phase II RG7716 Roche RG7906 Roche Phase l/II NXT007 in-house RG6321 Roche Phase l LUNA18 in-house GC33 in-house ERY974 in-house － － － Hemophilia A Solid tumors Solid tumors codrituzumab HCC Mode of Action Modality (Dosage form) pH-dependent binding humanized anti-IL-6 monoclonal antibody Antibody (SC) Anti-amyloid-beta human monoclonal antibody Antibody (SC) Antisense oligonucleotide targeting HTT mRNA Nucleic acid (IV) Microdystrophin gene therapy Gene therapy (Intramuscular injection) Anti-C5 recycling antibody Antibody (SC) Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous injection) Japan － Partial TAAR1 agonist Small molecule (Oral) US・EU 2025 and beyond Anti-C5 recycling antibody Antibody (SC) Global － Anti-coagulation factor IXa/X bispecific antibody Antibody (SC) Japan Japan Global Global Global － － － RAS inhibitor Mid-size molecule (Oral) Anti-Glypican-3 humanized monoclonal antibody Antibody (IV) Anti-Glypican-3/CD3 bispecific antibody Antibody (IV) Roche Roche Sarepta** Roche Roche Roche Roche Roche － － － － ranibizumab delivery system） (Port Diabetic macular edema Neovascular age-related macular degeneration 2024 2024 Humanized anti-VEGF monoclonal antibody Fragment Fab Antibody (injection via implant) Roche Roche Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 14 ■Oncology ■Immunology ■Neuroscience ■Hematology ■Ophthalmology ■Other Diseases Development code Origin Generic name Product name Indication # Additional indication (Combination drug) Mode of Action Modality (Dosage form) Partner Country/region Global Projected submission － mosunetuzumab Follicular lymphoma (3rd Line) Japan 2024 Solid tumors Solid tumors Solid tumors cobimetinib Solid tumors cibisatamab Solid tumors glofitamab Hematologic tumors Solid tumors efmarodocokin alfa Inflammatory bowel disease Neuromuscular disease prasinezumab Parkinson’s disease semorinemab Alzheimer’s disease Alzheimer’s disease Endometriosis STA551 in-house SOF10/RG6440 in-house SPYK04 in-house RG7828 Roche RG7421 Exelixis RG7802 Roche RG6026 Roche RG6194 Roche RG7880 Roche GYM329/ RG6237 in-house RG7935 Prothena RG6100 AC Immune RG6102 MorphoSys AMY109 in-house RG7992 Roche － － － － － － － Development discontinued ** Sarepta manages the global study including Japan Global Global Japan Japan Japan Japan Japan Global Japan Japan Japan Global － － － － － － － － － － － － Anti-CD137 agonistic Switch antibody Antibody (IV) Anti-latent TGF-β1 monoclonal antibody Antibody (IV) － Small molecule (Oral) Anti-CD20/CD3 bispecific antibody Antibody (IV) MEK inhibitor Small molecule (Oral) Anti-CEA/CD3 bispecific antibody Antibody (IV) Anti-CD20/CD3 bispecific antibody Antibody (IV) Anti-HER2/CD3 bispecific antibody Antibody (IV) Human IL-22 fusion protein Non-antibody protein (IV) Anti-latent myostatin sweeping antibody Antibody (SC) Anti-α-synuclein monoclonal antibody Antibody (IV) Anti-tau humanized monoclonal antibody Antibody (IV) Anti-amyloid beta/TfR1 fusion protein Antibody (IV) － Antibody (SC) Anti-FGFR1/KLB bispecific antibody Antibody (SC) Roche － － Roche Roche Roche Roche Roche Roche Roche Roche Roche Roche － Roche In principle, completion of first dose is regarded as the start of clinical studies in each phase. * Added due to changes in development pipeline disclosure standards Non-alcoholic steatohepatitis Japan － Changes from the last announcement on February 3, 2022 Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 15 Oncology Hematology Ophthalmology – RG7716 – RG7716 Other diseases – RG7828 Phase I (Follicular lymphoma [3rd Line]: development started) – SKY59/RG6107 Phase II (Sickle cell disease: development started in the United States and Europe) Filed → Approved (age-related macular degeneration associated with subfoveal choroidal neovascularization) Filed → Approved (diabetic macular edema (DME)) – RG6321 (Port delivery system) – RG6321 (Port delivery system) Phase I / II (nAMD: development started) Phase I/II (DME: development started) – RG7992 Phase I (Non-alcoholic steatohepatitis: development discontinued) R&D Activities For the changes during the FY2022 (January 1 – March 31), please refer to page 4 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the first quarter of the fiscal year 2022).” Changes from April 1 to April 25, 2022 are as follows: Immunology – The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) and has granted Priority Review for the humanized anti-human IL-6 receptor monoclonal antibody MRA/RG1569 (Product name: Actemra) for the treatment of COVID-19 in Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 16 hospitalized adults who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), in April 2022. CKI27/VS-6766 － Development pipeline [Attached table] (Major Chugai originated developments licensed out to 3rd party excluding Roche) Development code In-house/licensee Generic name Product name Indication # Additional Indication (combination) Stage Country/region Mode of Action Modality (Dosage form) Licensee (Granted rights ) RAF/MEK inhibitor Small molecule (Oral) Verastem (exclusive global license for the manufacturing, development and marketing) CIM331 nemolizumab Mitchga Itching associated with atopic dermatitis (only when existing treatment is insufficiently effective) Approved (March 2022) Japan Anti-IL-31 receptor A humanized monoclonal antibody Antibody (SC) Maruho (rights for development and marketing in the skin disease area for the Japanese market) Galderma (exclusive global license for the development and marketing excluding Japan and Taiwan) OWL833/ LY3502970 － Type 2 diabetes Obesity Oral non-peptidic GLP-1 receptor agonist Small molecule (Oral) Eli Lilly and Company (worldwide development and commercialization rights) Progress made in R&D activities of major Chugai originated developments licensed out to 3rd party excluding Roche during the period from January 1, 2022 to April 25, 2022 was as follows. – In Japan, Maruho obtained approval for the anti-IL-31 receptor A humanized monoclonal antibody CIM331 (Product name: Mitchga) for the treatment of itching associated with atopic dermatitis (only when existing treatment is insufficiently effective) in March 2022. Ovarian cancer (defactinib) NSCLC (defactinib) Prurigo nodularis Atopic dermatitis CKD associated pruritus Phase II Global Phase II Global Phase II/III Japan Phase III Global Phase II/III Global Phase II Global Phase II Global Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 17 Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of April 25, 2022) Product Indication Development Status Development Request Third development request Avastin Additional Q2W dosage and administration for ovarian cancer Evaluated by the Review Committee in December 2021 as eligible for public knowledge-based application; application approved February 4, 2022, by the Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council Fourth development request Neuroendocrine tumor Submitted company opinion and waiting for evaluation by committee Cerebral edema induced by radiation necrosis Submitted company opinion and waiting for evaluation by committee Xeloda Avastin Neutrogin Combination therapy with chemotherapy including fludarabine for relapsed/refractory acute myeloid leukemia Evaluated by the Review Committee in December 2021 as eligible for public knowledge-based application; application approved February 4, 2022, by the Second Committee on New Drugs, Pharmaceutical Affairs and Food Sanitation Council Major clinical trials in oncology field Expected Indication Treatment RG7446 (Tecentriq) Study design Study name Stage Planned filing year NSCLC [1st line] NSCLC [stage III] NSCLC [2nd line] NSCLC (neoadjuvant) NSCLC (adjuvant) SCLC Urothelial carcinoma (UC) Muscle-invasive bladder cancer (adjuvant) Prostate cancer [2nd line] Renal cell carcinoma (adjuvant) Renal cell carcinoma [2nd line] Early breast cancer Ovarian cancer HCC (adjuvant) PD-L1 positive: Tecentriq ± RG6058 Tecentriq + RG6058 vs. durvalumab Tecentriq + cabozantinib vs. docetaxel Chemo ± Tecentriq Tecentriq vs. best supportive care Tecentriq + chemo ± Avastin Tecentriq + chemo ± RG6058 Tecentriq ± chemo vs. chemo Tecentriq Tecentriq + cabozantinib vs. novel hormonal therapy Tecentriq cabozantinib ± Tecentriq TNBC (adjuvant): paclitaxel ± Tecentriq TNBC (neoadjuvant): nab-paclitaxel ± Tecentriq carboplatin + paclitaxel + Avastin ± Tecentriq Tecentriq + Avastin vs. active surveillance SKYSCRAPER-01 Phase III SKYSCRAPER-03 Phase III CONTACT-01 Phase III Phase III IMpower030 Phase III IMpower010 BEAT-SC Phase III SKYSCRAPER-02 Phase III Phase III IMvigor130 IMvigor011 Phase III CONTACT-02 Phase III IMmotion010 Phase III CONTACT-03 Phase III IMpassion030 Phase III IMpassion031 Phase III Phase III IMagyn050 Phase III IMbrave050 2023 2024 2023 2023 Filed 2023 – 2023 2024 – 2022 2023 2022 2023 2025 and beyond HCC (intermediate stage) Tecentriq + Avastin + TACE vs. TACE TALENTACE Phase III 2025 and beyond HCC [2nd line] Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib IMbrave251 Phase III 2025 and beyond Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 18 Treatment Expected Indication Study design Study name Stage Planned filing year RG7440 (ipatasertib) RG7596 (polatuzumab vedotin) DLBCL Head and neck carcinoma (adjuvant) Tecentriq Esophageal cancer Tecentriq + RG6058 vs. Tecentriq vs. placebo Prostate cancer [1st line] castration-resistant: abiraterone ± RG7440 IMvoke010 Phase III SKYSCRAPER-07 Phase III IPATential150 Phase III 2022 2024 2023 Rituxan + Chemo ± RG7596 POLARIX Phase III Filed RG6264 AF802 (Alecensa) RG6171 / SERD Breast cancer NSCLC (adjuvant) Breast cancer Breast cancer (adjuvant) Follicular lymphoma [2nd line] RG6264 (SC) + chemo vs. Herceptin (IV) + Perjeta (IV) + chemo ALK fusion-positive: Alecensa vs. chemo HR positive: RG6171 + palbocicilib ± Letrozole HR positive: RG6171 vs. endocrine therapy RG7828 + lenalidomide vs Rituxan + lenalidomide RG7828 Follicular lymphoma [3rd line] RG7828 FeDeriCa ALINA persevERA lidERA CELESTIMO Mosun Phase III Phase III Phase III Phase III Phase III Phase I (domestic) 2022 2023 2025 and beyond 2025 and beyond 2025 and beyond 2024 2024 RG6396 NSCLC RG6396 vs. platinum-based chemotherapy ± pembrolizumab AcceleRET-Lung Phase III FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of April 25, 2022) Alterations Cancer type Relevant drugs Activated EGFR gene alterations NSCLC afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate, dacomitinib hydrate EGFR exon 20 T790M alterations osimertinib mesilate alectinib hydrochloride, crizotinib, ceritinib, brigatinib entrectinib capmatinib hydrochloride hydrate dabrafenib mesilate, trametinib dimethyl sulfoxide ALK fusion genes ROS1 fusion genes MET exon 14 skipping alterations BRAF V600E alterations amplification positive) KRAS/NRAS wild-type Microsatellite instability-high Microsatellite instability-high Tumor mutational burden-high BRAF V600E and V600K alterations Malignant melanoma dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib ERBB2 copy number alterations (HER2 gene Breast cancer trastuzumab (genetical recombination) cetuximab (genetical recombination), panitumumab (genetical recombination) Colorectal cancer Solid tumors nivolumab (genetical recombination) pembrolizumab (genetical recombination) pembrolizumab (genetical recombination) Chugai Pharmaceutical Co., Ltd. (4519) Supplementary Materials for the 1st quarter of FY2022 (IFRS) 19 NTRK1/2/3 fusion gene BRCA1/2 alterations BRCA1/2 alterations FGFR2 fusion genes entrectinib, larotrectinib sulfate Ovarian cancer Prostate cancer olaparib olaparib Biliary Tract Cancer pemigatinib * Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of April 25, 2022) Alterations Cancer type Relevant drugs Activated EGFR gene alterations NSCLC afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate EGFR exon 20 T790M alterations osimertinib mesilate ALK fusion genes ROS1 fusion genes NTRK1/2/3 fusion gene BRCA1/2 alterations Solid tumors Prostate cancer entrectinib entrectinib olaparib alectinib hydrochloride, crizotinib, ceritinib